Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate - KIVIRID

Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

Authors: Jiang-Yi Wang, Guo-Peng Yu, Long Li, Guo-Wen Lin, Ding-Wei Ye

Published: 2022-01-24

DOI: 10.1186/s40779-021-00364-x

Source: Full article

Abstract

No abstract found.